Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance

Hikma Ustekinumab Deal Signed In Late August; Sandoz Oncology Pipeline Boosted

Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.

twin targets
BioThera has quickly out-licensed bevacizumab and ustekinumab • Source: Alamy

China’s Bio-Thera Solutions has quickly struck a second biosimilar licensing agreement with a major industry player, offloading rights to its BAT1706 proposed bevacizumab biosimilar to Sandoz in the US, Europe outside of Russia, Canada and “selected other countries” not covered by other partnerships.

Under the terms of the firms’ agreement, Sandoz noted, Bio-Thera Solutions will receive an upfront and milestone payments and is...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.